New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
05:06 EDTOSIROsiris Therapeutics successfully defends key stem cell patent challenge
Osiris Therapeutics announced the successful conclusion of a patent challenge in Australia by an opponent whose identity under Australian law was not disclosed. The patent at issue covers the administration of mesenchymal stem cells, or MSCs, including Prochymal, for the treatment of inflammatory conditions involving the gastrointestinal tract, including Crohn's disease and ulcerative colitis. As acknowledged in the Australian Official Journal of Patents Supplement, all claims to the patent will be maintained in full. The claims specifically include the use of allogeneic MSCs, an attribute central to making an off-the-shelf MSC product possible.
News For OSIR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
16:41 EDTOSIROsiris evaluates the establishment of an international subsidiary
Osiris Therapeutics developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced that it is evaluating the establishment of an international, ex-U.S. subsidiary in recognition of its expanding research and commercial business operations. The company is currently evaluating different locations, including United Kingdom, Singapore and Switzerland.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use